Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 2, 2013, Pages 221-228

  Taniguchi, Masatomo ^a   Fukagawa, Masafumi ^b   Fujii, Naohiko ^c   Hamano, Takayuki ^d   Shoji, Tetsuo ^e   Yokoyama, Keitaro ^f   Nakai, Shigeru ^g   Shigematsu, Takashi ^h   Iseki, Kunitoshi ⁱ   Tsubakihara, Yoshiharu ^d  

^a KYUSHU UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c Hyogo Prefectural Children's Hospital   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁱ UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

Author keywords

Chronic kidney disease mineral and bone disorders; Guidelines; Japan; Mortality; Priority

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL;

AGED; CALCIUM; COHORT STUDIES; FEMALE; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; SURVIVAL RATE; TIME FACTORS;

EID: 84875766786     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12030     Document Type: Article

References (37)

1. Moe S, Drüeke T, Cunningham J etal. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2006;69:1945-1953.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney failure. Am J Kidney Dis 2003;42(Suppl 3):S1-S201.
3. Noodzij M, Korevaar JC, Boeschoten EW etal. The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005;46:925-932.
4. Wang M, Hercz G, Sherrard DJ etal. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836-844.
5. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-525.
6. Nakai S, Masakane I, Akiba T etal. Overview of regular dialysis treatment in Japan as of 31 December 2006. Ther Apher Dial 2008;12:428-456.
7. Nakai S, Akiba T, Kazama J etal. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2008;12:49-54.
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76:S1-S130.
9. Kalantar-Zadeh K, Kuwae N, Regidor DL etal. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-780.
10. Block GA, Klassen PS, Lazarus M etal. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
11. Tentori F, Blayney MJ, Albert JM etal. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519-530.
12. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-1793.
13. Young EW, Albert JM, Satayathum S etal. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-1187.
14. Tangri N, Wagner M, Griffith JL etal. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis 2011;57:415-421.
15. Palmar SC, Hayen A, Macaskill P etal. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease. A systematic review and meta-analysis. JAMA 2011;305:1119-1127.
16. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lala A etal. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005;46:68-77.
17. Floege J, Kim J, Ireland E etal. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948-1955.
18. Block GA, Hulbert-Shearon TE, Levin NW etal. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
19. Blayney MJ, Pisoni RL, Bragg-Gresham JL etal. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008;74:655-663.
20. Shinzato T, Nakai S, Akiba T etal. Report on the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. Kidney Int 1996;55:700-712.
21. Akiba T, Nakai S, Shinzato T etal. Why has the gross mortality of dialysis patients increased in Japan? Kidney Int 2000;57:S60-S65.
22. Iseki K, Nakai S, Yamagata K etal. Tachycardia as a predictor of poor survival in chronic haemodialysis patients. Nephrol Dial Transplant 2011;26:963-969.
23. Daugirdas JT. The post: pre dialysis plasma urea nitrogen ratio to estimate Kt/V and NPCR: validation. Int J Artif Organs 1989;12:420-427.
24. Kalantar-Zadeh K, Supasyndh O, Lehn RS etal. Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. J Ren Nutr 2003;42:761-773.
25. Cox DR. Regression models and life tables. J Royal Stat Soc [B] 1972;74:187-220.
26. Danese MD, Belozeroff V, Smirnakis K etal. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1423-1429.
27. Avram MM, Mittman N, Myint MM etal. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001;38:1351-1357.
28. Stevens LA, Djurdjev O, Chardew S etal. Calcium, phosphate, and parathyroid hand as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004;15:770-779.
29. Shoji T, Shinohara K, Kimoto E etal. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004;19:179-184.
30. Teng M, Wolf M, Ofsthun MN etal. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125.
31. Melamed ML, Eustace JA, Plantinga L etal. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006;70:351-357.
32. Tentori F, Hunt WC, Stidley CA etal. Medical Directors of Dialysis Clinic Inc: mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858-1865.
33. Kovesdy CP, Ahmadzadeh S, Anderson JE etal. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008;168:397-403.
34. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J etal. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008;74:1070-1078.
35. Cunningham J, Danese M, Olson K etal. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-1800.
36. Block GA, Zaun D, Smits G etal. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010;78:578-589.
37. Isakova T, Gutierrez OM, Chang Y etal. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2008;20:388-396.